News Brabio, 1st Generic Version of Copaxone for Relapsing MS, Launched in UK Brabio, 1st Generic Version of Copaxone for Relapsing MS, Launched in UK by Jose Marques Lopes, PhD | January 26, 2018 Share this article: Share article via email Copy article link Brabio (glatiramer acetate injection), the first generic alternative to CopaxoneĀ for relapsing multiple sclerosis (MS) patients, was recently launched in the U.K. at an equivalent higher dose, its maker,Ā Mylan, announced. Similar to Copaxone Ā ā developed by TevaĀ āĀ Brabio is now available at a 40 mg/ml dose. Both medications are intended to be taken three times per week and at least 48 hours apart. Brabio is expected to be sold at a lower cost than Copaxone, as the U.K.ās National Health Service (NHS) is aiming to broaden the use of best-value therapies within its Medicines Value Programme. This program aims to improve health outcomes while keeping costs affordable. Research estimates that over 100,000 people have MS in the U.K., with the highest prevalence being observed in Scotland. About 6,000 new cases are diagnosed each year.Ā āBringing a more affordable, more accessible treatment option to market for patients with [MS] has been a priority for Mylan,ā Jacek Glinka, president of Mylan Europe, said in a press release. āWe are dedicated to this important patient community and continued efforts to bring lower-cost, high-quality therapeutic equivalent versions of Copaxone to market in the UK and around the world.ā The launch of Brabio follows the U.K. Court of Appealās refusal this month to accept Teva’s request for an appeal of earlier ruling by the country’s High Court of Justice in favor of Mylan and its partner Synthon. All claims of infringement related to Teva’s U.K. patent covering CopaxoneĀ 40 mg/mL were found invalid. This decision made Brabio’s launch at this dose possible in the U.K. Synthon is responsible for developing and supplying Mylanās European glatiramer acetate injection products, with exclusive rights across Europe. The medicationās high dose (40 mg/mL) was granted marketing authorization in multiple European markets in October 2017. A lower dose (20 mg/mL), taken once/day, had been launched earlier across the continent. The U.S. Food and Drug Administration approved both lower and higher doses of Mylanās generic versions of Copaxone in October 2017. Results from a Phase 3 study (NCT01489254), called Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone or GATE, were important to these approvals. The study, which ended in early 2015,Ā showed that that the generic glatiramer acetate formulation had equivalent efficacy to CopaxoneĀ in adults with relapsing MS. The generic version reduced brain lesions similar to the brand-name treatment, and showed a positive safety and tolerability profile. A study reporting GATE results was published in JAMA Neurology in December 2015. Print This Page About the Author Jose Marques Lopes, PhD JosĆ© holds a PhD in neuroscience from the University of Porto, Portugal. After postdocs at Weill Connell Medicine and Western University, where he studied the processes driving hypertension and Alzheimerās disease, he moved on in 2016 to a career in science writing and communication. JosĆ© is the author of several peer-reviewed papers and a book chapter and has presented his research in numerous international meetings. Tags Copaxone, generic, Glatiramer acetate, Mylan, Teva, U.K.
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8